166 related articles for article (PubMed ID: 33880639)
1. First-line methadone for cancer pain: titration time analysis.
Mammana G; Bertolino M; Bruera E; Orellana F; Vega F; Peirano G; Bunge S; Armesto A; Dran G
Support Care Cancer; 2021 Nov; 29(11):6335-6341. PubMed ID: 33880639
[TBL] [Abstract][Full Text] [Related]
2. Methadone as first-line opioid treatment for cancer pain in a developing country palliative care unit.
Peirano GP; Mammana GP; Bertolino MS; Pastrana T; Vega GF; Russo J; Varela G; Vignaroli E; Ruggiero R; Armesto A; Camerano G; Dran G
Support Care Cancer; 2016 Aug; 24(8):3551-6. PubMed ID: 27022964
[TBL] [Abstract][Full Text] [Related]
3. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
4. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study.
Porta-Sales J; Garzón-Rodríguez C; Villavicencio-Chávez C; Llorens-Torromé S; González-Barboteo J
Oncologist; 2016 Aug; 21(8):981-7. PubMed ID: 27306912
[TBL] [Abstract][Full Text] [Related]
6. Improved Pain Control in Terminally Ill Cancer Patients by Introducing Low-Dose Oral Methadone in Addition to Ongoing Opioid Treatment.
Fürst P; Lundström S; Klepstad P; Runesdotter S; Strang P
J Palliat Med; 2018 Feb; 21(2):177-181. PubMed ID: 28792784
[TBL] [Abstract][Full Text] [Related]
7. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
[TBL] [Abstract][Full Text] [Related]
8. Methadone as First-line Opioid for the Management of Cancer Pain.
Mercadante S; Adile C; Ferrera P; Pallotti MC; Ricci M; Bonanno G; Casuccio A
Oncologist; 2022 Apr; 27(4):323-327. PubMed ID: 35380722
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-Related Pain: The EQUIMETH2 Trial (Methadone for Cancer-Related Pain).
Poulain P; Berleur MP; Lefki S; Lefebvre D; Chvetzoff G; Serra E; Tremellat F; Derniaux A; Filbet M;
J Pain Symptom Manage; 2016 Nov; 52(5):626-636.e1. PubMed ID: 27693901
[TBL] [Abstract][Full Text] [Related]
10. Methadone titration in opioid-resistant cancer pain.
Scholes CF; Gonty N; Trotman IF
Eur J Cancer Care (Engl); 1999 Mar; 8(1):26-9. PubMed ID: 10362950
[TBL] [Abstract][Full Text] [Related]
11. Methadone switching for refractory cancer pain.
Ding H; Song Y; Xin W; Sun J; Zhong L; Zhou Q; He C; Gong L; Fang L
BMC Palliat Care; 2022 Nov; 21(1):191. PubMed ID: 36324113
[TBL] [Abstract][Full Text] [Related]
12. High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain.
Amato F; Ceniti S; Mameli S; Pisanu GM; Vellucci R; Palmieri V; Consoletti L; Magaldi D; Notaro P; Marcassa C
Support Care Cancer; 2017 Oct; 25(10):3051-3058. PubMed ID: 28470370
[TBL] [Abstract][Full Text] [Related]
13. Switching to Intravenous Methadone in Advanced Cancer Patients: A Retrospective Analysis.
Mercadante S; Cascio AL; Casuccio A
J Pain Symptom Manage; 2023 Oct; 66(4):287-292. PubMed ID: 37236430
[TBL] [Abstract][Full Text] [Related]
14. Opioid Rotation to Methadone for Refractory Cancer Pain: A Case Series.
Khoo SY; Aziz FA; Nambbiar P
J Pain Palliat Care Pharmacother; 2019; 33(3-4):125-130. PubMed ID: 31638444
[TBL] [Abstract][Full Text] [Related]
15. Methadone as a First-Line Opioid in Cancer Pain Management: A Systematic Review.
Mercadante S; Bruera E
J Pain Symptom Manage; 2018 Mar; 55(3):998-1003. PubMed ID: 29101087
[TBL] [Abstract][Full Text] [Related]
16. The Use of Low-Dose Methadone as Add-On to Regular Opioid Therapy in Cancer-Related Pain at End of Life: A National Swedish Survey in Specialized Palliative Care.
Fürst P; Lundström S; Klepstad P; Strang P
J Palliat Med; 2020 Feb; 23(2):226-232. PubMed ID: 31436477
[No Abstract] [Full Text] [Related]
17. The role of methadone in cancer-induced bone pain: a retrospective cohort study.
Sulistio M; Wojnar R; Key S; Kwok J; Al-Rubaie Z; Michael N
Support Care Cancer; 2021 Mar; 29(3):1327-1335. PubMed ID: 32627056
[TBL] [Abstract][Full Text] [Related]
18. Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study.
Hagen NA; Fisher K; Stiles C
J Palliat Med; 2007 Apr; 10(2):331-7. PubMed ID: 17472503
[TBL] [Abstract][Full Text] [Related]
19. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
20. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study.
Bruera E; Palmer JL; Bosnjak S; Rico MA; Moyano J; Sweeney C; Strasser F; Willey J; Bertolino M; Mathias C; Spruyt O; Fisch MJ
J Clin Oncol; 2004 Jan; 22(1):185-92. PubMed ID: 14701781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
